SAN DIEGO, March 15, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2016 and provided an update on its corporate activities and product pipeline. "Cidara continued to make progress throughout the year in moving our development programs forward," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "We executed on our CD101 clinical…

Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track Company to Host Conference Call Today at 5:30 a.m. PT SAN DIEGO, Feb. 21, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported that the randomized, controlled Phase 2 RADIANT clinical trial in acute vulvovaginal candidiasis (VVC) did not…

Topline Data Expected in First Quarter 2017 SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the RADIANT trial, a Phase 2 randomized trial evaluating the safety, tolerability and efficacy of two topical treatment regimens of the novel echinocandin antifungal, CD101, in women with moderate to severe acute vulvovaginal candidiasis (VVC). CD101 topical is the first and only agent in…

Data Showcase Compound's Discovery through Development and Potential to Expand Echinocandin Utility Across Multiple Infectious-Disease Indications SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating the company's novel echinocandin antifungal CD101 appear in the December 5 online issue of the journal Antimicrobial Agents and Chemotherapy (AAC). These latest findings add to the growing body of published scientific evidence that…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego from December 3-6, 2016. CD101 is Cidara's lead antifungal drug candidate and the only long-acting antifungal in the echinocandin class. "Patients with blood cancers…

SAN DIEGO, Nov. 10, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2016 and provided an update on its corporate activities and product pipeline. "Cidara made major progress in the third quarter and achieved significant clinical and corporate milestones. We enrolled the first patient in our Phase 2 STRIVE study of CD101 IV in candidemia, announced CD201 as…

Data Will Highlight the Potential Broad Clinical Utility and Subcutaneous Administration of CD101 for Invasive Fungal Infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 as a potential treatment for invasive fungal infections will be presented at the joint conference of the International Immunocompromised Host Society (ICHS) and INFOCUS Latinomérica from November…

SAN DIEGO, Nov. 08, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced it will participate in the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016. Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 8:00 a.m. EST (5:00 a.m. PST). The conference is being held in New York City. A live audio webcast and replay will be available in the…

SAN DIEGO, Nov. 02, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, and Square 1 Bank, a division of Pacific Western Bank, announced they have entered into an agreement for a $20 million credit facility. Proceeds from the facility will provide working capital to support Cidara's CD101 and CD201 programs which are in development to treat serious fungal and multi-drug resistant bacterial infections.…

Data Highlight Safety and Efficacy of CD101 IV and CD101 Topical for the Treatment of Fungal Infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 as a potential treatment for serious infections will be presented at the 2016 American College of Clinical Pharmacy (ACCP) Annual Meeting in Hollywood, Florida from October 23-26…